Viewing Study NCT06333860


Ignite Creation Date: 2025-12-25 @ 2:09 AM
Ignite Modification Date: 2025-12-28 @ 8:57 PM
Study NCT ID: NCT06333860
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-23
First Post: 2024-03-21
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
Sponsor: AbbVie
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module